BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics. 2015;10:431-445. [PMID: 25923331 DOI: 10.1080/15592294.2015.1039216] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Wei Z, Shan Y, Tao L, Liu Y, Zhu Z, Liu Z, Wu Y, Chen W, Wang A, Lu Y. Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis. Mol Carcinog 2017;56:2317-31. [DOI: 10.1002/mc.22686] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
2 Wang L, Ahn YJ, Asmis R. Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis. Atherosclerosis 2021;328:23-32. [PMID: 34077868 DOI: 10.1016/j.atherosclerosis.2021.05.002] [Reference Citation Analysis]
3 Kochanek SJ, Close DA, Johnston PA. High Content Screening Characterization of Head and Neck Squamous Cell Carcinoma Multicellular Tumor Spheroid Cultures Generated in 384-Well Ultra-Low Attachment Plates to Screen for Better Cancer Drug Leads. Assay Drug Dev Technol 2019;17:17-36. [PMID: 30592624 DOI: 10.1089/adt.2018.896] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
4 Schizas D, Mastoraki A, Naar L, Tsilimigras DI, Katsaros I, Fragkiadaki V, Karachaliou GS, Arkadopoulos N, Liakakos T, Moris D. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. Curr Med Chem 2020;27:6099-111. [PMID: 31309879 DOI: 10.2174/0929867326666190712160842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
5 Wu N, Zhu Y, Xu X, Zhu Y, Song Y, Pang L, Chen Z. The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma. J Cancer 2018;9:987-97. [PMID: 29581778 DOI: 10.7150/jca.22861] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
6 Wetzel A, Scholtka B, Schumacher F, Rawel H, Geisendörfer B, Kleuser B. Epigenetic DNA Methylation of EBI3 Modulates Human Interleukin-35 Formation via NFkB Signaling: A Promising Therapeutic Option in Ulcerative Colitis. Int J Mol Sci 2021;22:5329. [PMID: 34069352 DOI: 10.3390/ijms22105329] [Reference Citation Analysis]
7 Li H, Li H, Waresijiang Y, Chen Y, Li Y, Yu L, Li Y, Liu L. Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma. Exp Ther Med 2020;20:315-24. [PMID: 32536999 DOI: 10.3892/etm.2020.8697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Huo J, Xu S, Lam KP. FAIM: An Antagonist of Fas-Killing and Beyond. Cells 2019;8:E541. [PMID: 31167518 DOI: 10.3390/cells8060541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Feingold PL, Surman DR, Brown K, Xu Y, McDuffie LA, Shukla V, Reardon ES, Crooks DR, Trepel JB, Lee S, Lee MJ, Gao S, Xi S, McLoughlin KC, Diggs LP, Beer DG, Nancarrow DJ, Neckers LM, Davis JL, Hoang CD, Hernandez JM, Schrump DS, Ripley RT. Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma. Mol Cancer Ther 2018;17:2013-23. [PMID: 29934340 DOI: 10.1158/1535-7163.MCT-17-1240] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
10 Wang P, Zhao H, Ren F, Zhao Q, Shi R, Liu X, Liu J, Li Y, Li Y, Liu H, Chen J. [Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors]. Zhongguo Fei Ai Za Zhi 2020;23:91-100. [PMID: 32093453 DOI: 10.3779/j.issn.1009-3419.2020.02.04] [Reference Citation Analysis]
11 Lundstrom K. Epigenetics, Nutrition, Disease and Drug Development. Curr Drug Discov Technol 2019;16:386-91. [PMID: 29692252 DOI: 10.2174/1570163815666180419154954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Lin DC, Wang MR, Koeffler HP. Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients. Gastroenterology. 2018;154:374-389. [PMID: 28757263 DOI: 10.1053/j.gastro.2017.06.066] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 18.0] [Reference Citation Analysis]
13 Kołat D, Kałuzińska Ż, Bednarek AK, Płuciennik E. The biological characteristics of transcription factors AP-2α and AP-2γ and their importance in various types of cancers. Biosci Rep 2019;39:BSR20181928. [PMID: 30824562 DOI: 10.1042/BSR20181928] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
14 Yang YM, Hong P, Xu WW, He QY, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther 2020;5:229. [PMID: 33028804 DOI: 10.1038/s41392-020-00323-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
15 Ahrens TD, Timme S, Ostendorp J, Bogatyreva L, Hoeppner J, Hopt UT, Hauschke D, Werner M, Lassmann S. Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity. Lab Invest 2016;96:307-16. [PMID: 26692290 DOI: 10.1038/labinvest.2015.148] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
16 Gaur P, Hunt CR, Pandita TK. Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget 2016;7:48644-55. [PMID: 27102294 DOI: 10.18632/oncotarget.8777] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
17 Chen Y, Feng H, Zhang H, Li X. High expression of DNA methyltransferase 1 in Kazakh esophageal epithelial cells may promote malignant transformation induced by N -methyl- N ′-nitro- N -nitrosoguanidine. Hum Exp Toxicol 2019;38:1060-8. [DOI: 10.1177/0960327119851254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Dai F, Du P, Chang Y, Ji E, Xu Y, Wei C, Li J. Downregulation of MiR-199b-5p Inducing Differentiation of Bone-Marrow Mesenchymal Stem Cells (BMSCs) Toward Cardiomyocyte-Like Cells via HSF1/HSP70 Pathway. Med Sci Monit 2018;24:2700-10. [PMID: 29715263 DOI: 10.12659/MSM.907441] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Peng H, Wang LG, Wang XZ, Liu AJ. The correlation between XIAP gene polymorphisms and esophageal squamous cell carcinoma susceptibility and prognosis in a Chinese population. Pathol Res Pract 2017;213:1482-8. [PMID: 29037837 DOI: 10.1016/j.prp.2017.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Hodjat M, Jourshari PB, Amirinia F, Asadi N. 5-Azacitidine and Trichostatin A induce DNA damage and apoptotic responses in tongue squamous cell carcinoma: An in vitro study. Arch Oral Biol 2021;133:105296. [PMID: 34735927 DOI: 10.1016/j.archoralbio.2021.105296] [Reference Citation Analysis]
21 Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med 2016;6:a026831. [PMID: 27599530 DOI: 10.1101/cshperspect.a026831] [Cited by in Crossref: 374] [Cited by in F6Publishing: 339] [Article Influence: 62.3] [Reference Citation Analysis]
22 Yu S, Jia B, Liu N, Yu D, Zhang S, Wu A. Fumonisin B1 triggers carcinogenesis via HDAC/PI3K/Akt signalling pathway in human esophageal epithelial cells. Sci Total Environ 2021;787:147405. [PMID: 34000555 DOI: 10.1016/j.scitotenv.2021.147405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shi Y, Xiang Z, Yang H, Khan S, Li R, Zhou S, Ullah S, Zhang J, Liu B. Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma. Aging (Albany NY) 2021;13:15336-52. [PMID: 34047714 DOI: 10.18632/aging.203091] [Reference Citation Analysis]
24 Ma S, Liu T, Xu L, Wang Y, Zhou J, Huang T, Li P, Liu H, Zhang Y, Zhou X, Cui Y, Zang X, Wang Y, Guan F. Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway. J Cell Physiol 2019;234:22400-10. [PMID: 31120582 DOI: 10.1002/jcp.28805] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 Abdelfatah E, Kerner Z, Nanda N, Ahuja N. Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol. 2016;9:560-579. [PMID: 27366224 DOI: 10.1177/1756283x16644247] [Cited by in Crossref: 62] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
26 Spohn L, Fichter C, Werner M, Lassmann S. Subcellular localization of EGFR in esophageal carcinoma cell lines. J Cell Commun Signal 2016;10:41-7. [PMID: 26582583 DOI: 10.1007/s12079-015-0308-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Kejík Z, Jakubek M, Kaplánek R, Králová J, Mikula I, Martásek P, Král V. Epigenetic agents in combined anticancer therapy. Future Medicinal Chemistry 2018;10:1113-30. [DOI: 10.4155/fmc-2017-0203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
28 Lopomo A, Coppedè F. Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers. Expert Rev Gastroenterol Hepatol 2018;12:49-62. [PMID: 28856927 DOI: 10.1080/17474124.2017.1374853] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Gerlitz G. The Emerging Roles of Heterochromatin in Cell Migration. Front Cell Dev Biol 2020;8:394. [PMID: 32528959 DOI: 10.3389/fcell.2020.00394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
30 Panda A, Bhanot G, Ganesan S, Bajpai M. Gene Expression in Barrett's Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:5971. [PMID: 34885081 DOI: 10.3390/cancers13235971] [Reference Citation Analysis]
31 Yin Y, Du L, Li X, Zhang X, Gao Y. miR-133a-3p suppresses cell proliferation, migration, and invasion and promotes apoptosis in esophageal squamous cell carcinoma. J Cell Physiol 2019;234:12757-70. [PMID: 30537034 DOI: 10.1002/jcp.27896] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
32 Lopes N, Correia MP, Henrique R, Jerónimo C. Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes. Int J Mol Sci 2020;21:E3522. [PMID: 32429269 DOI: 10.3390/ijms21103522] [Reference Citation Analysis]
33 Verma M, Kumar V. Epigenetic Drugs for Cancer and Precision Medicine. Epigenetics of Aging and Longevity. Elsevier; 2018. pp. 439-51. [DOI: 10.1016/b978-0-12-811060-7.00021-8] [Cited by in Crossref: 12] [Article Influence: 3.0] [Reference Citation Analysis]
34 Huang X, Li X, Situ M, Huang L, Wang J, He T, Yan Q, Xie X, Zhang Y, Gao Y, Li Y, Rong T, Wang M, Cai Q, Fu J. Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1. Cancer Letters 2018;414:294-300. [DOI: 10.1016/j.canlet.2017.10.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
35 Macedo-Silva C, Miranda-Gonçalves V, Henrique R, Jerónimo C, Bravo I. The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance. Genes (Basel) 2019;10:E927. [PMID: 31739546 DOI: 10.3390/genes10110927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
36 Lohse I, Al-Ali H, Volmar CH, D Alvarez Trotta A, Brothers SP, Capobianco AJ, Wahlestedt C. Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma. PLoS One 2018;13:e0203173. [PMID: 30212533 DOI: 10.1371/journal.pone.0203173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
38 Pickering OJ, Breininger SP, Underwood TJ, Walters ZS. Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma. Cancers (Basel) 2021;13:4084. [PMID: 34439236 DOI: 10.3390/cancers13164084] [Reference Citation Analysis]
39 Xu P, Hu G, Luo C, Liang Z. DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opin Ther Pat 2016;26:1017-30. [PMID: 27376512 DOI: 10.1080/13543776.2016.1209488] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
40 Shieh J, Tang Y, Hu F, Huang W, Wang Y, Jen J, Liao S, Lu Y, Yeh Y, Wang T, Lin P, Wang Y. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer: Antitumor effects and signals of TMU-35435. Int J Cancer 2017;140:2375-86. [DOI: 10.1002/ijc.30664] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
41 Sant S, Johnston PA. The production of 3D tumor spheroids for cancer drug discovery. Drug Discov Today Technol. 2017;23:27-36. [PMID: 28647083 DOI: 10.1016/j.ddtec.2017.03.002] [Cited by in Crossref: 150] [Cited by in F6Publishing: 140] [Article Influence: 30.0] [Reference Citation Analysis]
42 El Bahhaj F, Denis I, Pichavant L, Delatouche R, Collette F, Linot C, Pouliquen D, Grégoire M, Héroguez V, Blanquart C, Bertrand P. Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy. Theranostics 2016;6:795-807. [PMID: 27162550 DOI: 10.7150/thno.13725] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]